Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.

Haematologica - 1 Jun 2011

Hornakova Tekla, Springuel Lorraine, Devreux Julien, Dusa Alexandra, Constantinescu Stefan N, Knoops Laurent, Renauld Jean-Christophe

Abstract excerpt

BACKGROUND: Activating mutations in JAK1 and JAK2 have been described in patients with various hematologic malignancies including acute lymphoblastic leukemia and myeloproliferative neoplasms, leading to clinical trials with JAK inhibitors. While there has been a tremendous effort towards the dev...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding, Competitive
Share to CHO Cells
Share to Cricetulus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Order

Share to Janus Kinase 1

Share to Janus Kinase 2

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to STAT5 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 21393331
DOI: 10.3324/haematol.2010.036350
PMCID: PMC3105646

Genes

JAK1
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21393331-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.PMID 21393331Read ↗

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.Semantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.Semantic proximity Read ↗

Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase InhibitorSemantic proximity Read ↗

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.Semantic proximity Read ↗

Therapeutically Targetable ALK Mutations in Leukemia.Semantic proximity Read ↗

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemiaSemantic proximity Read ↗

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.Semantic proximity Read ↗

TP-0903 is active in models of drug-resistant acute myeloid leukemia.Semantic proximity Read ↗

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.Semantic proximity Read ↗

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.